Spinal Restoration, Inc. Completes Enrollment of the Phase III Study of the Biostat® System
7/11/2012 10:30:55 AM
AUSTIN, Texas--(BUSINESS WIRE)--Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain. The study is being conducted at 20 centers across the U.S.